Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Peter Impey

- PMLiVE

AstraZeneca’s Truqap plus Faslodex granted EC approval to treat advanced breast cancer

More than 550,000 new cases of breast cancer were diagnosed in Europe in 2022

- PMLiVE

The Communiqué Awards announces PAPYRUS as 2024 charity partner

PAPYRUS Prevention of Young Suicide aims to shatter the stigma that still surrounds suicide

- PMLiVE

Sanofi and Belharra Therapeutics enter $700m immunological disease collaboration

The partnership will utilise Belharra’s platform to identify and advance small molecules against immunology targets

- PMLiVE

Researchers develop AI blood test to predict Parkinson’s seven years before symptom onset

The neurodegenerative condition currently affects nearly ten million people worldwide

- PMLiVE

WHO publishes latest report on development of antibacterial agents worldwide

AMR is designated as one of the top ten global public health threats facing humanity

- PMLiVE

Key sustainability trends and challenges facing pharmaceutical companies

Looking at the opportunities and benefits of implementing sustainable procurement practices

- PMLiVE

Roche and Ascidian enter neurological disease partnership worth over $1.8bn

More than three billion people worldwide were living with a neurological condition in 2021

- PMLiVE

Merck’s adult-specific pneumococcal vaccine Capvaxive granted FDA approval

The vaccine is designed to protect against the strains responsible for the majority of adult invasive pneumococcal disease

- PMLiVE

AbbVie’s IL-23 inhibitor Skyrizi approved by FDA to treat ulcerative colitis in adults

The inflammatory bowel disease affects more than one million people in the US

- PMLiVE

Johnson & Johnson’s investigational nipocalimab shows promise in Sjögren’s disease

The chronic autoimmune disease is estimated to affect four million people worldwide

- PMLiVE

Sustainability and environmentalism in the pharmaceutical industry

In this Q&A, Claire Knapp, CEO of Havas Lynx, talks to PME about why the path to sustainability in healthcare is fraught with significant challenges and highlights the need for...

David Miller at ITN studio talking of real world evidence, HEOR, and market access

Genesis Research Group Announces Participation of CEO David W. Miller in New ITN Business Healthcare Program

Genesis Research Group, led by newly appointed CEO, David W. Miller, is spotlighted in June’s launch of ITN Business’ “Advancing Healthcare” program for its ‘innovate differently’ approach to supporting life...

Genesis Research Group

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links